Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
-
- STATUS
- Recruiting
-
- End date
- Jan 4, 2028
-
- participants needed
- 410
-
- sponsor
- Hospices Civils de Lyon
Summary
Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric acids during digestion. It is also important for the regulation of cell growth of the gastric mucosal.
In a healthy person, progastrin is not detectable in the peripheral blood. However, progastrin is abnormally released in the blood of patients with different cancers (colorectal, gastric, ovarian, breast, cervix uterus, melanoma) The gene GAST coding for progastrin is a direct target gene of the WNT/-catenin oncogenic pathway. The activation of this oncogenic pathway is an early event in cancer development.
Chronic activation of the WNT/-catenin oncogenic pathway occurs in almost all human solid tumors and is a central mechanism in cancer biology that induces cellular proliferation, blocking of differentiation leading to primary tumor growth and metastasis formation.
Progastrin measured in the peripheral blood of patients on treatments, could be a new powerful marker for diagnosis and prognosis at different stages.
Details
| Condition | Ovarian Cancer, Ewing's Family Tumors, Liver Cancer, Kidney Cancer, Kidney Disease, Digestive System Neoplasms, Prostate Cancer, Glioblastoma multiforme, Islet Ce417ll Cancer, Prostate Disorders, Recurrent Ovarian Cancer, Breast Cancer, Cancer/Tumors, HEPATIC NEOPLASM, cancer of the esophagus, cancer of the pancreas, Rectal disorder, LIVER DISEASE, prostate carcinoma, Bladder Cancer, Pulmonary Disease, colorectal neoplasm, urinary tract neoplasm, bladder disorder, cancer, ovarian, Bladder Disorders, Esophageal Cancer, Neoplasms, Lung Neoplasm, Gastric Cancer, Bladder Carcinoma, carcinoma lung, Lymphoma, B-Cell, b-cell lymphomas, Renal Cancer, Lung Disease, cancer ovarian, Liver Disorders, malignancies, Melanoma, Kidney Disease (Pediatric), cancer, pancreatic, bladder tumor, cancer, breast, b cell lymphomas, cancer, colorectal, Prostate Cancer, Early, Recurrent, tumors, colorectal, b cell lymphoma, Metastatic Melanoma, skin cancer, liver cancers, Colorectal Cancer, Malignant neoplasm of kidney, ovarian carcinomas, Skin Cancer, head and neck cancer, Pancreatic Cancer, Liver Disease, esophagus cancer, malignancy, Lymphoma, breast carcinoma, B-Cell Lymphoma, Pancreatic disorder, Rectal Disorders, carcinoma of the bladder, Ovarian disorder, melanoma, primary malignant neoplasm, cancer of the ovary, malignant tumor, prostate cancers, pancreatic cancers, cancer of the head and neck, cancer, liver, Colon cancer; rectal cancer, Endometrial Carcinoma, Cancer (Pediatric), Urothelial Cancer, colorectal cancers, Non-Hodgkin's Lymphoma, oesophageal carcinoma, malignant tumors, Esophageal Diseases, Gastric Carcinoma, Esophageal Disorders, Lung Cancer, Stomach Cancer, Urologic Cancer, Head and Neck Cancer, oesophageal cancer, cancer, hepatic, Ovarian Function, ovarian tumors, Colon Cancer Screening, Endometrial Cancer, Pancreatic Disorders, primary cancer, Malignant Melanoma, cancer, renal, cancers, lung carcinoma, Stomach Discomfort, Esophageal Carcinoma, cancer, hepatocellular, Gastropathy, colorectal tumor, Bronchial Neoplasm, Uterine Cancer, Malignant neoplasm of prostate, bladder cancer, glioblastoma, Nephropathy, gastric cancers, Neoplasm of unspecified nature of digestive system, Glioblastoma Multiforme, Prostatic disorder, HEPATOCELLULAR CARCINOMA, Cancer, Breast Cancer Diagnosis |
|---|---|
| Treatment | Blood draws |
| Clinical Study Identifier | NCT03787056 |
| Sponsor | Hospices Civils de Lyon |
| Last Modified on | 25 July 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer